NCT06093698View on ClinicalTrials.gov

An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

94

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Recurrent or Metastatic Solid Tumors

Interventions

BIOLOGICAL

Recombinant Anti-EpCAM-CD3 Antibody Injection

Intravenous Infusion

All Listed Sponsors

lead

ITabMed Co., Ltd.

INDUSTRY